Abstracts tagged "infliximab"

Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Ana Martínez^1,2, Chamaida Plasencia^2,3, Victoria Navarro-Compán², Borja Hernández-Breijo², Dora Pascual-Salcedo², Pilar Nozal⁴, Cristina Diego⁴, Irene Monjo^2,3, Laura Nuño^3,5 and Alejandro Balsa^2,6, ¹Immunology. La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴La Paz University Hospital, Immunology, Madrid, Spain, ⁵Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
Abstract Number: 602 • 2018 ACR/ARHP Annual Meeting
Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring
Silje Watterdal Syversen¹, Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Johanna Gehin³, Cato Mork⁴, Tore Kvien⁵, Jorgen Jahnsen⁶, Nils Bolstad³ and Espen A. Haavardsholm⁵, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴None, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway
Background/Purpose: The purpose is to develop an individualised treatment strategy based on Therapeutic drug monitoring (TDM) in order to optimise efficacy of Infliximab (INX) treatment.…
Abstract Number: 455 • 2017 ACR/ARHP Annual Meeting
Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab
Lorie A. Ellis¹, Ismail Simsek², Lin Xie³, Adesuwa Ogbomo³, Dennis Parenti⁴, Kavitha Goyal⁴ and Yusuf Yazici⁵, ¹Janssen HECOR Immunology, Horsham, PA, ²Guven Hospital, Ankara, Turkey, ³STATinMED Research Inc., Ann Arbor, MI, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Biosimilar infliximab (CT-P13) was first approved in Europe in 2013.This study compared treatment (tx) patterns of Turkish pts with a diagnosis of rheumatoid arthritis(RA)…
Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting
Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis
Joseph Tkacz¹, Edward Lee², Robert Low², Jeffrey Stark², Mohamed Yassine² and Brenna Brady¹, ¹Health Analytics LLC, Columbia, MD, ²UCB Pharma, Smyrna, GA
Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
Abstract Number: 1041 • 2017 ACR/ARHP Annual Meeting
Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US
Janna Radtchenko, Yolaine Smith, Jonathan Kish and Bruce Feinberg, Specialty Solutions, Cardinal Health, Dallas, TX
Background/Purpose: A biosimilar product is a biological product highly similar to another FDA-approved biological product, reference product, and has no clinically meaningful differences in safety…
Abstract Number: 1280 • 2017 ACR/ARHP Annual Meeting
Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University
Katelyn Banschbach¹, Ellen Go² and Stacey Tarvin³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Pediatrics, Indiana University School of Medicine, Indianapolis, IN, ³Riley Hospital for Children, Indiana University, Indianapolis, IN
Background/Purpose: To analyze the clinical outcomes of TNF-inhibitors as a steroid-sparing agent in the treatment of juvenile dermatomyositis (JDM). Methods: We performed a retrospective chart…
Abstract Number: 2296 • 2017 ACR/ARHP Annual Meeting
Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?
Ryan Funk¹, Valentina Shakhnovich², Leon van Haandel³ and Mara L Becker⁴, ¹University of Kansas Medical Center, Kansas City, KS, ²Gastroenterology and Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ³Clinical Pharmacology, Medical Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Infliximab (IFX) effectiveness is impacted in part by immunogenicity and the development of drug neutralizing anti-drug antibodies, thus methotrexate is commonly co-administered to minimize…
Abstract Number: 2318 • 2017 ACR/ARHP Annual Meeting
Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy
Eileen Pagano¹, Myriam Kline² and B. Anne Eberhard³, ¹Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ²Biostatistics Unit, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ³Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY
Background/Purpose: Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-a). It is known to be effective and often used in the…
Abstract Number: 2320 • 2017 ACR/ARHP Annual Meeting
Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years
Annelle Reed¹, Surabhi S. Vinod², Jamelle Maxwell³, Esraa M. A. Eloseily^4,5, Matthew L. Stoll⁴ and Randy Q. Cron⁴, ¹Pediatric rheumatology, Childrens of Alabama, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Childrens of Alabama, Birmingham, AL, ⁴Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, Assiut University, Assiut, Egypt
Background/Purpose: The goals of this report are to describe various therapeutic protocols, volume of intravenous (IV) infusions, and associated adverse events at the University of…
Abstract Number: 2800 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Joe Sexton¹, Inge C Olsen³, Nils Bolstad⁴, Merete Lorentzen⁵, Espen A. Haavardsholm⁶, Cato Mork⁷, Jorgen Jahnsen⁸ and Tore K Kvien⁹, ¹Dept Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of cancer and Molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway, ⁸Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁹Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) , Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 2904 • 2017 ACR/ARHP Annual Meeting
Efficacy and Tolerance of TNF Alpha Inhibitor (TNFI) Treatment in Cardiac Sarcoidosis (CS)
Deborah Puyraimond-Zemmour¹, Catherine Chapelon-Abric², David Saadoun³, Diane Bouvry⁴, Marc Ruivard⁵, Marc Andre⁶, Laurent Perard⁷, Pascal Sève⁸ and Patrice Cacoub⁹, ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France, Paris, France, ²AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ³Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, ⁴Hopital Avicenne, Department of Pneumology, Bobigny, France, Bobigny, France, ⁵CHU Estaing, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ⁶CHU Montpied, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ⁷Department of Internal Medicine, Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France, ⁸Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Background/Purpose: CS is a life-threatening condition that accounts for 85% of sarcoidosis-related deaths in Japan and 13-25% in America. The objective is to evaluate the…
Abstract Number: 50 • 2017 Pediatric Rheumatology Symposium
Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients
Daniel Groth¹, Sivia Lapidus², Simona Nativ² and Maria Perez³, ¹Goryeb Children's Hospital, Morristown, NJ, ²Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, ³Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ
Background/Purpose: Occurrence of psoriasis while on TNFα antagonists is a paradoxical effect of agents that treat psoriasis, and is described in larger cohorts of inflammatory…
Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting
Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway
Guro Løvik Goll^1,2, Inge C Olsen³, Kristin K Jorgensen⁴, Merete Lorentzen⁵, Nils Bolstad⁶, Espen A. Haavardsholm⁷, Knut EA Lundin⁸, Cato Mork⁹, Jorgen Jahnsen⁴, Tore K Kvien³ and the NOR-SWITCH study group, ¹Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway, ⁸Dept of gastroenterology, Rikshospitalet, Oslo, Norway, ⁹Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 1122 • 2016 ACR/ARHP Annual Meeting
Infliximab Suppresses the Monocyte Chemotaxis in Human TNF-Transgenic Mice
Qi Quan Huang¹, Robert Birkett¹, Elyssa L Roberts² and Richard M. Pope³, ¹Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²northwestern University, Chicago, IL, ³Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Macrophages in rheumatoid arthritis (RA) synovium produce high levels of inflammatory cytokines/chemokines and play the pivotal role in promoting inflammation and joint destruction. Treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].